DE69638120D1 - Konditionell replizierende virale Vektoren und ihre Verwendung - Google Patents

Konditionell replizierende virale Vektoren und ihre Verwendung

Info

Publication number
DE69638120D1
DE69638120D1 DE69638120T DE69638120T DE69638120D1 DE 69638120 D1 DE69638120 D1 DE 69638120D1 DE 69638120 T DE69638120 T DE 69638120T DE 69638120 T DE69638120 T DE 69638120T DE 69638120 D1 DE69638120 D1 DE 69638120D1
Authority
DE
Germany
Prior art keywords
image
viral
conditionally replicating
vector
replicating viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69638120T
Other languages
English (en)
Inventor
Boro Dropulic
Paula M S Pitha-Rowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69638120D1 publication Critical patent/DE69638120D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69638120T 1995-11-28 1996-11-27 Konditionell replizierende virale Vektoren und ihre Verwendung Expired - Lifetime DE69638120D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56345995A 1995-11-28 1995-11-28

Publications (1)

Publication Number Publication Date
DE69638120D1 true DE69638120D1 (de) 2010-03-11

Family

ID=24250568

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69638120T Expired - Lifetime DE69638120D1 (de) 1995-11-28 1996-11-27 Konditionell replizierende virale Vektoren und ihre Verwendung
DE69626681T Expired - Lifetime DE69626681T2 (de) 1995-11-28 1996-11-27 Konditionell-replizierende virale vektoren und ihre verwendung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69626681T Expired - Lifetime DE69626681T2 (de) 1995-11-28 1996-11-27 Konditionell-replizierende virale vektoren und ihre verwendung.

Country Status (19)

Country Link
EP (2) EP0871757B1 (de)
JP (2) JP2000503527A (de)
KR (1) KR100537458B1 (de)
CN (3) CN100390291C (de)
AT (2) ATE455858T1 (de)
AU (3) AU1124997A (de)
BR (1) BR9612574A (de)
CA (1) CA2236868C (de)
CZ (1) CZ294170B6 (de)
DE (2) DE69638120D1 (de)
DK (1) DK0871757T3 (de)
ES (1) ES2188802T3 (de)
HK (1) HK1060152A1 (de)
IL (2) IL124636A0 (de)
NO (1) NO329619B1 (de)
NZ (1) NZ324157A (de)
PT (1) PT871757E (de)
RU (1) RU2270250C2 (de)
WO (1) WO1997020060A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037669A4 (de) * 1997-12-12 2003-04-02 Cell Genesys Inc Therapeutische nutzung von lentiviralen vektoren
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
AU9307501A (en) * 2000-09-22 2002-04-02 Virxsys Improved conditionally replicating vectors, methods for their production and use
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
HUE036103T2 (hu) 2007-12-11 2018-06-28 Univ North Carolina Chapel Hill Polipurin szakaszon módosított retrovirális vektorok
KR102162111B1 (ko) * 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
CA3225013A1 (en) * 2015-02-24 2016-09-01 Bioatla, Llc Conditionally active proteins
CN104711294A (zh) * 2015-04-02 2015-06-17 扬州大学 一种基于禽网状内皮组织增生症病毒ltr的真核表达线性化载体的构建方法及应用
GB2543730A (en) * 2015-05-26 2017-05-03 Andrzejewski Slawomir Use of replication competent vector to eradicate viral latency presented on human immunodeficiency virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1994026877A1 (en) * 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
ES2260376T3 (es) * 1994-01-05 2006-11-01 Gene Shears Pty Limited Ribozimas dirigidas contra una secuencia tat del vih.
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof

Also Published As

Publication number Publication date
JP2000503527A (ja) 2000-03-28
CN1940076A (zh) 2007-04-04
IL124636A (en) 2009-12-24
ATE234362T1 (de) 2003-03-15
EP0871757B1 (de) 2003-03-12
JP4384146B2 (ja) 2009-12-16
DE69626681T2 (de) 2004-02-12
NO329619B1 (no) 2010-11-22
EP1380650A1 (de) 2004-01-14
AU1124997A (en) 1998-06-19
AU767620B2 (en) 2003-11-20
EP0871757A1 (de) 1998-10-21
CN100390291C (zh) 2008-05-28
ES2188802T3 (es) 2003-07-01
CN1207775A (zh) 1999-02-10
AU2004200663B2 (en) 2007-07-05
CA2236868A1 (en) 1997-06-05
CA2236868C (en) 2014-01-21
AU1000001A (en) 2001-05-17
BR9612574A (pt) 2000-04-25
KR100537458B1 (ko) 2008-09-08
KR19990071728A (ko) 1999-09-27
RU2270250C2 (ru) 2006-02-20
DK0871757T3 (da) 2003-07-14
CZ162498A3 (cs) 1998-12-16
IL124636A0 (en) 1998-12-06
CZ294170B6 (cs) 2004-10-13
NO982418L (no) 1998-07-27
HK1060152A1 (en) 2004-07-30
PT871757E (pt) 2003-08-29
NO982418D0 (no) 1998-05-27
ATE455858T1 (de) 2010-02-15
EP1380650B1 (de) 2010-01-20
JP2007014341A (ja) 2007-01-25
DE69626681D1 (de) 2003-04-17
NZ324157A (en) 2000-10-27
CN1651577A (zh) 2005-08-10
AU2004200663A1 (en) 2004-04-08
WO1997020060A1 (en) 1997-06-05

Similar Documents

Publication Publication Date Title
CY1120209T1 (el) Αλληλουχιες αδενο-εξαρτωμενου ιου (aav) οροτυπου 9, φορεις που τον περιεχουν και χρησεις αυτων
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
PT836648E (pt) Virus mva recombinante e sua utilizacao
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
DE69519521D1 (de) Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
IL207348A0 (en) Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them, and use thereof in the manufacture of medicinal products for producing recombinant proteins in vivo
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
NO883896L (no) Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.
ATE455858T1 (de) Konditionell replizierende virale vektoren und ihre verwendung
DK0839194T3 (da) Varianter af P53-proteinet og terapeutiske anvendelser
EP1012603A4 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
DK0843731T3 (da) Adenovirusvektorer til genterapi
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
DK0817859T3 (da) Rekombinante DNA vektorer til Genterapi
ATE269064T1 (de) Impfstoffe gegen den hepatitis b und c virus
WO2001011063A3 (de) Kombinationsvektoren für den gentransfer, verfahren zu ihrer herstellung und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition